Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord blood transplantation with StemRegenin-1 expanded hematopoietic stem cells
2016-002383-13Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of StemRegenin 1 in hematopoietic malignancies, sponsored by Erasmus MC. Primary endpoint: Feasibility of single-unit UCBT with one SR-1 expanded unit. Started Sep 2016; status: active.
02
Drugs
StemRegenin 1
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2016-002383-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002383-13.